drugset / Trial / NCT00006036

Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors

NCT00006036 ↗

Phase 1 Completed 14 enrolled NCIC Clinical Trials Group
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of liposomal lurtotecan plus cisplatin in treating patients who have advanced or metastatic solid tumors.

Timeline

Start
2000-03-22
Primary completion
2002-09-26
Completion
2009-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 25 mg/m2 —
Subject lurtotecan Small molecule 0.7 mg/m2 —
Subject lurtotecan Small molecule 0.9 mg/m2 —